Wall Street Zen cut shares of Entero Therapeutics (NASDAQ:GRDX – Free Report) from a hold rating to a strong sell rating in a report released on Saturday,Wall Street Zen reports.
Entero Therapeutics Trading Down 6.1%
NASDAQ GRDX opened at $3.72 on Friday. Entero Therapeutics has a 12 month low of $1.87 and a 12 month high of $6.93. The stock has a 50-day simple moving average of $3.73 and a 200 day simple moving average of $3.43. The company has a market capitalization of $26.52 million, a PE ratio of -1.96 and a beta of 1.86.
Institutional Trading of Entero Therapeutics
A hedge fund recently bought a new stake in Entero Therapeutics stock. DRW Securities LLC acquired a new position in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned about 1.45% of Entero Therapeutics at the end of the most recent reporting period. 12.30% of the stock is currently owned by hedge funds and other institutional investors.
Entero Therapeutics Company Profile
Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.
Featured Stories
- Five stocks we like better than Entero Therapeutics
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
